Avidity Biosciences, Inc. Rings the Closing Bell in Celebration of its IPO

ABOUT THIS EVENT

Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs™), rang the Nasdaq Closing Bell remotely from across the world. 

In honor of the occasion, Sarah Boyce, President & CEO, rang the Closing Bell alongside employees from around the world in a virtual bell ringing ceremony.